{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:18:29Z","timestamp":1758381509346,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.xphs.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T21:58:48Z","timestamp":1587160728000},"page":"2356-2361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetic Model-Based Evaluation of Circadian Variations in Plasma 5-Fluorouracil Concentrations During Long-Term Infusion in Rats: A Comparison With Oral Anticancer Prodrugs"],"prefix":"10.1016","volume":"109","author":[{"given":"Shinji","family":"Kobuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sakaeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2020.04.005_bib1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.xphs.2020.04.005_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","article-title":"Therapeutic drug monitoring of 5-fluorouracil","volume":"78","author":"Lee","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2020.04.005_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2020.04.005_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.xphs.2020.04.005_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/ijms.7.48","article-title":"Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III\/IVa esophageal squamous cell carcinoma","volume":"7","author":"Kuwahara","year":"2010","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.xphs.2020.04.005_bib6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00280-016-3184-6","article-title":"Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial","volume":"78","author":"Denda","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2020.04.005_bib7","first-page":"381","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice","volume":"15","author":"Wilhelm","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.xphs.2020.04.005_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12885-015-1075-6","article-title":"Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant- rate infusion","volume":"15","author":"Fleming","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xphs.2020.04.005_bib9","first-page":"6193","article-title":"Fluctuation in plasma 5-fluorouracil concentration during continuous 5-fluorouracil infusion for colorectal cancer","volume":"35","author":"Matsumoto","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.xphs.2020.04.005_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2017.11.021","article-title":"Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats","volume":"112","author":"Kobuchi","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.04.005_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ejps.2018.08.004","article-title":"Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats","volume":"123","author":"Kobuchi","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.04.005_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(96)06315-2","article-title":"Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity","volume":"252","author":"Tateishi","year":"1996","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.xphs.2020.04.005_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/bdd.1851","article-title":"A\u00a0predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer","volume":"34","author":"Kobuchi","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.xphs.2020.04.005_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00280-016-3105-8","article-title":"Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil","volume":"78","author":"Kobuchi","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2020.04.005_bib15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/00498254.2015.1100767","article-title":"Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats","volume":"46","author":"Kobuchi","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2020.04.005_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/cas.13883","article-title":"Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX","volume":"110","author":"Shirasu","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.xphs.2020.04.005_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers10110454","article-title":"Severe neutropenia is associated with better clinical outcomes in patients with advanced pancreatic cancer who receive modified FOLFIRINOX therapy","volume":"10","author":"Yamada","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xphs.2020.04.005_bib18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1200\/JCO.2002.20.6.1683","article-title":"Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors","volume":"20","author":"Adjei","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.xphs.2020.04.005_bib19","first-page":"2930","article-title":"Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas","volume":"42","author":"Au","year":"1982","journal-title":"Cancer Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:34Z","timestamp":1758360574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920301982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022354920301982"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.04.005","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetic Model-Based Evaluation of Circadian Variations in Plasma 5-Fluorouracil Concentrations During Long-Term Infusion in Rats: A Comparison With Oral Anticancer Prodrugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}